215 related articles for article (PubMed ID: 31727580)
1. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
Grant AD; Charalambous S; Tlali M; Karat AS; Dorman SE; Hoffmann CJ; Johnson S; Vassall A; Churchyard GJ; Fielding KL
Lancet HIV; 2020 Jan; 7(1):e27-e37. PubMed ID: 31727580
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial.
Fielding KL; Charalambous S; Hoffmann CJ; Johnson S; Tlali M; Dorman SE; Vassall A; Churchyard GJ; Grant AD
Trials; 2015 Mar; 16():125. PubMed ID: 25872501
[TBL] [Abstract][Full Text] [Related]
3. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.
Peter JG; Zijenah LS; Chanda D; Clowes P; Lesosky M; Gina P; Mehta N; Calligaro G; Lombard CJ; Kadzirange G; Bandason T; Chansa A; Liusha N; Mangu C; Mtafya B; Msila H; Rachow A; Hoelscher M; Mwaba P; Theron G; Dheda K
Lancet; 2016 Mar; 387(10024):1187-97. PubMed ID: 26970721
[TBL] [Abstract][Full Text] [Related]
4. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.
Gupta-Wright A; Corbett EL; van Oosterhout JJ; Wilson D; Grint D; Alufandika-Moyo M; Peters JA; Chiume L; Flach C; Lawn SD; Fielding K
Lancet; 2018 Jul; 392(10144):292-301. PubMed ID: 30032978
[TBL] [Abstract][Full Text] [Related]
5. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
7. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.
Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA;
Lancet HIV; 2018 May; 5(5):e231-e240. PubMed ID: 29653915
[TBL] [Abstract][Full Text] [Related]
8. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.
Iwuji CC; Orne-Gliemann J; Larmarange J; Balestre E; Thiebaut R; Tanser F; Okesola N; Makowa T; Dreyer J; Herbst K; McGrath N; Bärnighausen T; Boyer S; De Oliveira T; Rekacewicz C; Bazin B; Newell ML; Pillay D; Dabis F;
Lancet HIV; 2018 Mar; 5(3):e116-e125. PubMed ID: 29199100
[TBL] [Abstract][Full Text] [Related]
9. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
10. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D;
N Engl J Med; 2020 Jun; 382(25):2397-2410. PubMed ID: 32558469
[TBL] [Abstract][Full Text] [Related]
11. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
12. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
13. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial.
Fairall L; Bachmann MO; Lombard C; Timmerman V; Uebel K; Zwarenstein M; Boulle A; Georgeu D; Colvin CJ; Lewin S; Faris G; Cornick R; Draper B; Tshabalala M; Kotze E; van Vuuren C; Steyn D; Chapman R; Bateman E
Lancet; 2012 Sep; 380(9845):889-98. PubMed ID: 22901955
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S; Wachira S; Musoro G; Rajapakse C; Etyang T; Abach J; Spyer MJ; Wavamunno P; Nyondo-Mipando L; Chidziva E; Nathoo K; Klein N; Hakim J; Gibb DM; Walker AS; Pett SL;
PLoS Med; 2018 Dec; 15(12):e1002706. PubMed ID: 30513108
[TBL] [Abstract][Full Text] [Related]
15. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial.
Maskew M; Brennan AT; Fox MP; Vezi L; Venter WDF; Ehrenkranz P; Rosen S
PLoS Med; 2020 Aug; 17(8):e1003226. PubMed ID: 32853271
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
17. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
[TBL] [Abstract][Full Text] [Related]
18. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
[TBL] [Abstract][Full Text] [Related]
19. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Rangaka MX; Wilkinson RJ; Boulle A; Glynn JR; Fielding K; van Cutsem G; Wilkinson KA; Goliath R; Mathee S; Goemaere E; Maartens G
Lancet; 2014 Aug; 384(9944):682-90. PubMed ID: 24835842
[TBL] [Abstract][Full Text] [Related]
20. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.
Mfinanga S; Chanda D; Kivuyo SL; Guinness L; Bottomley C; Simms V; Chijoka C; Masasi A; Kimaro G; Ngowi B; Kahwa A; Mwaba P; Harrison TS; Egwaga S; Jaffar S;
Lancet; 2015 May; 385(9983):2173-82. PubMed ID: 25765698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
